Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15224399 | 0.83 | SMN1; SMN2 (0.41) | POLBSMN1; SMN2HSD17B10CXCR4CHRM5 | |
| SCHEMBL22444413 | 0.76 | — | — | |
| SCHEMBL2007452 | 0.76 | — | — | |
| SCHEMBL415783 | 0.72 | — | — | |
| SCHEMBL23599207 | 0.70 | — | — | |
| SCHEMBL615128 | 0.70 | — | — | |
| SCHEMBL4715 | 0.70 | — | — | |
| SCHEMBL13698656 | 0.70 | — | — | |
| Hydrochloric Acid SCHEMBL16486635 | 0.70 | — | — | |
| SCHEMBL7223824 | 0.70 | CHRM5 (0.33) | POLBSMN1; SMN2HSD17B10CXCR4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1462444-B1 | INTERMEDIATE FOR BIOTIN AND PROCESS FOR PRODUCING THE SAME | MITSUBISHI TANABE PHARMA CORP (JP) | 2009-09-16 | — | — | EP | claimed |
| US-20050038260-A1 | Intermediate for biotin and process for producing the same | API CORPORATION (JP) | 2005-02-17 | — | — | US | claimed |
| EP-1462444-A1 | INTERMEDIATE FOR BIOTIN AND PROCESS FOR PRODUCING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 2004-09-29 | — | — | EP | claimed |
| US-7799929-B2 | Biotin intermediate and process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| EP-1462444-B1 | INTERMEDIATE FOR BIOTIN AND PROCESS FOR PRODUCING THE SAME | MITSUBISHI TANABE PHARMA CORP (JP) | 2009-09-16 | — | — | EP | disclosed |
| EP-2098528-A2 | Biotin intermediate and process for preparing the same | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-09-09 | — | — | EP | disclosed |
| US-20080119655-A1 | Biotin intermediate and process for preparing the same | SEKI MASAHIKO | 2008-05-22 | — | — | US | disclosed |
| US-7335778-B2 | Intermediate for biotin and process for producing the same | TANABE SEIYAKU CO., LTD. (JP) | 2008-02-26 | — | — | US | disclosed |
| US-20050038260-A1 | Intermediate for biotin and process for producing the same | API CORPORATION (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1462444-A1 | INTERMEDIATE FOR BIOTIN AND PROCESS FOR PRODUCING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 2004-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119655-A1 | Biotin intermediate and process for preparing the same | BTD, BOLA2; BOLA2B, BCAT1 | POLB 1543/4885SMN1; SMN2 4588/4885HSD17B10 724/4885 |
| US-20050038260-A1 | Intermediate for biotin and process for producing the same | BTD, BCAT1, HLCS | POLB 1418/4885SMN1; SMN2 4723/4885HSD17B10 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.